7-year-old Simon Cancer Center already outmoded
The Indiana University Simon Cancer Center appears ill-suited for the future of cancer care and its own future is in question.
Cancer
Articles
Lilly pledges $60M to German firm to form research partnership
In a bid to get into the white-hot market for drugs that use the body’s immune system, Eli Lilly and Co. will spend $60 million to form a research partnership with Germany-based BioNTech.
Diabetes drug metformin show promise in cancer
Researchers at Purdue University, the Indiana University School of Medicine and the University of Wisconsin discovered a combination of two currently available drugs significantly slowed the growth of late-stage prostate cancer tumors in mice.
Recent wins worth $4B to Lilly market value
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Lilly cancer drug fares well in late-stage study
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
Costly drugs force cancer docs to weigh price with therapy
With new cancer drugs priced as high as $10,000 a month, and insurers tightening payment rules, patients who thought they were well covered increasingly find themselves having to make life-altering decisions about what they can afford.
Endocyte shares plunge 60 percent after drug trial is stopped
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
Cancer treatment makes Endocyte premium takeover target
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
Endocyte stock doubles after key approval in Europe
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
Indiana one of many states aiming to limit tanning
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
Three groups puzzled by woman’s $7 million bequest
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
Lilly lung cancer drug raises patient survival in trial
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
Small charity eases struggles of breast cancer patients
With volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients. Recipients have ranged in age from 18 to 90.
Sledge’s exit will keep IU program mostly intact
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Indiana Blood Center tapping new vein of revenue
Group sees role in cellular therapy as growth area with profit margins higher than core business.
Lilly cancer treatment fails trial in stomach cancer
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
Notre Dame receives $5M for adult stem cell research
The university says the gift from an alumnus will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, in hopes of accelerating discovery of new treatments for heart disease, diabetes and some cancers.
Cancer tools help Roche with Alzheimer’s drug
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
WellPoint enrolls IBM supercomputer at IU medical school
IBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying to teach it how to treat cancer.